James A. Sloand, MD, FACP, FASN is a nephrologist and an Adjunct Clinical Professor of Medicine within the Division of Kidney Diseases and Hypertension at the George Washington University School of Medicine and Health Sciences. Dr. Sloand is the Founder and Managing Director of JAS Renaissance LLC which serves to provide expert renal consultation to renal biopharmaceutical and device industries.
Dr. Sloand received his medical degree from St. Louis University School of Medicine and completed his Internal medicine residency at St. Luke’s Hospital/Washington University in St. Louis, Missouri. Following residency, he completed a nephrology fellowship at the University of Rochester in Rochester, NY and remained on faculty with extensive clinical practice, academic and research work for 24 years, achieving the position of Professor of Medicine. Dr. Sloand is a Fellow of the American College of Physicians and a Fellow of the American Society of Nephrology. During his tenure at Baxter Healthcare Corporation from 2007-2018, his responsibilities as Global Therapeutic Area Lead for Peritoneal Dialysis included new product development, global expansion and life-cycle management for existing products, and global educational initiatives. Jim was subsequently recruited to AstraZeneca Pharmaceuticals where he served as Senior Global Medical Affairs Leader in the Cardio-Vascular Renal Metabolism Division from 2018-2021.
Dr. Sloand has authored or co-authored more than 70 peer-reviewed publications, four nephrology textbook chapters, and has been an invited speaker at national and international nephrology congresses. He was recognized as “Best Teacher” within the faculty at the University of Rochester Department of Medicine over multiple years. When at Baxter, he directed a collaborative effort through the International Society of Peritoneal Dialysis to develop US, and later Global continuing medical educational programs dedicated to instructing surgeons, radiologists, and nephrologists in effective PD Catheter insertion techniques (PD catheter dysfunction being a prevalent reason for PD therapy failure).
Dr. Sloand also served as a pioneer member on the board of directors for the Kidney Health Initiative, a collaboration including the FDA and the ASN dedicated to catalyzing “innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases.” In 2017, Dr. Sloand received the John V. Heher Humanitarian Award from the National Kidney Foundation for “improving access to care for individuals with kidney disease and “outstanding dedication to the kidney community.”
Throughout his career, Jim has consistently educated, advocated and practiced his profession to improve the choices, medical care and quality of life for individuals with kidney disease.